These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37851297)

  • 1. Population Health Model Predicting the Long-Term Impact of Sotatercept on Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension (PAH).
    McLaughlin V; Alsumali A; Liu R; Klok R; Martinez EC; Nourhussein I; Bernotas D; Chevure J; Pausch C; De Oliveira Pena J; Lautsch D; Hoeper MM
    Adv Ther; 2024 Jan; 41(1):130-151. PubMed ID: 37851297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
    Hoeper MM; Badesch DB; Ghofrani HA; Gibbs JSR; Gomberg-Maitland M; McLaughlin VV; Preston IR; Souza R; Waxman AB; Grünig E; Kopeć G; Meyer G; Olsson KM; Rosenkranz S; Xu Y; Miller B; Fowler M; Butler J; Koglin J; de Oliveira Pena J; Humbert M;
    N Engl J Med; 2023 Apr; 388(16):1478-1490. PubMed ID: 36877098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)?
    Doggrell SA
    Expert Opin Biol Ther; 2023; 23(7):589-593. PubMed ID: 37269300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Immunogenicity on the Pharmacokinetics, Efficacy, and Safety of Sotatercept in a Phase III Study of Pulmonary Arterial Hypertension.
    Liao K; Mackenzie H; Ait-Oudhia S; Manimaran S; Zeng Y; Akers T; Yun T; de Oliveira Pena J
    Clin Pharmacol Ther; 2024 Mar; 115(3):478-487. PubMed ID: 38012534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPECTRA Phase 2b Study: Impact of Sotatercept on Exercise Tolerance and Right Ventricular Function in Pulmonary Arterial Hypertension.
    Waxman AB; Systrom DM; Manimaran S; de Oliveira Pena J; Lu J; Rischard FP
    Circ Heart Fail; 2024 May; 17(5):e011227. PubMed ID: 38572639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
    Humbert M; McLaughlin V; Gibbs JSR; Gomberg-Maitland M; Hoeper MM; Preston IR; Souza R; Waxman A; Escribano Subias P; Feldman J; Meyer G; Montani D; Olsson KM; Manimaran S; Barnes J; Linde PG; de Oliveira Pena J; Badesch DB;
    N Engl J Med; 2021 Apr; 384(13):1204-1215. PubMed ID: 33789009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sotatercept for Pulmonary Arterial Hypertension in the Inpatient Setting.
    Torbic H; Tonelli AR
    J Cardiovasc Pharmacol Ther; 2024; 29():10742484231225310. PubMed ID: 38361351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Navigating the Sotatercept landscape: A meta-analysis of clinical outcomes.
    Nasrollahizadeh A; Soleimani H; Nasrollahizadeh A; Hashemi SM; Hosseini K
    Clin Cardiol; 2024 Jan; 47(1):e24173. PubMed ID: 37819149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating Pulmonary Arterial Hypertension With Sotatercept: A Meta-Analysis.
    Uddin N; Ashraf MT; Sam SJ; Sohail A; Ismail SM; Paladini A; Syed AA; Mohamad T; Varrassi G; Kumar S; Khatri M
    Cureus; 2024 Jan; 16(1):e51867. PubMed ID: 38327917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial.
    Souza R; Badesch DB; Ghofrani HA; Gibbs JSR; Gomberg-Maitland M; McLaughlin VV; Preston IR; Waxman AB; Grünig E; Kopeć G; Meyer G; Olsson KM; Rosenkranz S; Lin J; Johnson-Levonas AO; de Oliveira Pena J; Humbert M; Hoeper MM
    Eur Respir J; 2023 Sep; 62(3):. PubMed ID: 37696565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the European Society of Cardiology/European Respiratory Society derived three- and four-strata risk stratification models in pulmonary arterial hypertension: introducing an internet-based risk stratification calculator.
    Ahmed A; Ahmed S; Kempe D; Rådegran G
    Eur Heart J Open; 2023 Mar; 3(2):oead012. PubMed ID: 36959867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.
    Kuwana M; Blair C; Takahashi T; Langley J; Coghlan JG
    Ann Rheum Dis; 2020 May; 79(5):626-634. PubMed ID: 32161055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.
    Chin KM; Rubin LJ; Channick R; Di Scala L; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF
    Circulation; 2019 May; 139(21):2440-2450. PubMed ID: 30982349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refined risk stratification, current treatment, and new therapeutic approaches in pulmonary arterial hypertension.
    Lange TJ
    Herz; 2023 Aug; 48(4):259-265. PubMed ID: 37085727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy of refractory pulmonary arterial hypertension.
    Ahmed MS; Ghallab M; Ostrow T; Nashawi M; Alagha Z; Levine A; Aronow WS; Lanier GM
    Expert Opin Pharmacother; 2023; 24(17):1861-1874. PubMed ID: 37698041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study.
    Gaine S; Sitbon O; Channick RN; Chin KM; Sauter R; Galiè N; Hoeper MM; McLaughlin VV; Preiss R; Rubin LJ; Simonneau G; Tapson V; Ghofrani HA; Lang I
    Chest; 2021 Jul; 160(1):277-286. PubMed ID: 33545163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk stratification in patients with pulmonary arterial hypertension at the time of listing for lung transplantation.
    Vicaire H; Pavec JL; Mercier O; Montani D; Boucly A; Roche A; Pradère P; Dauriat G; Feuillet S; Pichon J; Jevnikar M; Beurnier A; Jaïs X; Fadel E; Sitbon O; Humbert M; Savale L
    J Heart Lung Transplant; 2022 Sep; 41(9):1285-1293. PubMed ID: 35778258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical treatment of pulmonary hypertension in adults with congenital heart disease: updated and extended results from the International COMPERA-CHD Registry.
    Kaemmerer AS; Gorenflo M; Huscher D; Pittrow D; Ewert P; Pausch C; Delcroix M; Ghofrani HA; Hoeper MM; Kozlik-Feldmann R; Skride A; Stähler G; Vizza CD; Jureviciene E; Jancauskaite D; Gumbiene L; Ewert R; Dähnert I; Held M; Halank M; Skowasch D; Klose H; Wilkens H; Milger K; Jux C; Koestenberger M; Scelsi L; Brunnemer E; Hofbeck M; Ulrich S; Vonk Noordegraaf A; Lange TJ; Bruch L; Konstantinides S; Claussen M; Löffler-Ragg J; Wirtz H; Apitz C; Neidenbach R; Freilinger S; Nemes A; Opitz C; Grünig E; Rosenkranz S
    Cardiovasc Diagn Ther; 2021 Dec; 11(6):1255-1268. PubMed ID: 35070795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hospitalization-related costs associated with oral agents targeting the prostacyclin pathway for pulmonary arterial hypertension.
    McConnell J; Bilir SP; Xu Y; Tsang Y; Panjabi S
    J Med Econ; 2023; 26(1):1349-1355. PubMed ID: 37800591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term impact of add-on sequential triple combination therapy in pulmonary arterial hypertension: real world experience.
    Deshwal H; Weinstein T; Salyer R; Thompson J; Cefali F; Fenton R; Bondarsky E; Sulica R
    Ther Adv Respir Dis; 2023; 17():17534666231199693. PubMed ID: 37795626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.